Sengenics, a Leading Precision Medicine Focused Company, to Present at the Annual BIO CEO and Investor Conference
January 28, 2020SINGAPORE–(BUSINESS WIRE)–Sengenics, a leading precision medicine focused company, today announced that Dr Arif Anwar, CEO of Sengenics, will present a company overview at the 2020 BIO CEO and Investor Conference. The presentation will take place at 3:15 PM EST on Monday, February 10, 2020 in the Wilder room at the New York Marriott Marquis.
Dr Arif Anwar will present an overview of the commercialisation strategy of the company and applications of its patented KREXTM technology for autoimmune and cancer immunotherapy drug response and ADR prediction.
Sengenics is currently co-developing complementary and companion diagnostic tests for several autoimmune and cancer immunotherapy drugs through partnerships with top pharmaceutical companies. The company has commenced the process for obtaining FDA 510(k) approval for several of these tests and plans to launch them in 2020 and 2021.
Sengenics’ management team will also hold meetings with institutional investors and analysts from February 10 – 14 in New York. Accredited investors are invited to request a meeting during the conference through BIO’s One-on-One PartneringTM System.
About Sengenics
Sengenics is a precision medicine company that leverages its patented KREXTM technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREXTM can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.
Contacts
Media
Farah Elena
Marketing Manager
Sengenics Corporation Pte Ltd
[email protected]
Business Development and Partnerships
Andrew James Jackson
Global Business Unit Director – Pharma
Sengenics Corporation Pte Ltd
[email protected]